adverse event could have a material adverse effect on the Company’s results of operations and financial condition.
•
Climate change or legal, regulatory or market measures to address climate change may negatively affect the Company’s business, results of operations, cash flows and prospects.
•
Environmental, social and governance matters may impact the Company’s business and reputation.
•
Failure to attract and retain highly qualified personnel could affect the Company’s ability to successfully develop and commercialize products.
26
Table of Content
s
•
The Company may experience difficulties and delays in manufacturing certain of its products, including vaccines.
•
The Company’s business in China has grown in the past few years, and the importance of China to the Company’s overall pharmaceutical and vaccines business has increased accordingly. In 2024, the Company experienced lower sales of
Gardasil/Gardasil 9
in China and expects that sales of
Gardasil/Gardasil 9
in China will decline significantly in 2025.
•
The Company may not be able to realize the expected benefits of its investments in emerging markets.
•
The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.
•
Pharmaceutical products can develop unexpected safety or efficacy concerns.
•
Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company’s business.
•
Negative events in the animal health industry could have a material adverse effect on future results of operations and financial condition of the Company or its Animal Health business.
•
Biologics and vaccines carry unique risks and uncertainties, which could have a material adverse effect on the Company’s future results of operations and financial condition.
•
The health care industry in the U.S. has been, and will continue to be, subject to increasing regulation and political action.
•
The Company’s products, including products in development, cannot be marketed unless the Company obtains and maintains regulatory approval.
•
Developments following regulatory approval may adversely affect sales of the Company’s products.
•
The Company is subject to a variety of U.S. and international laws and regulations.
•
The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.
•
Adverse outcomes in current or future legal matters could negatively affect Merck’s business.
•
Product liability insurance for products may be limited, cost prohibitive or unavailable.
•
The Company is increasingly dependent on sophisticated software applications and computing infrastructure, including the use of cloud-based applications and environments. The Company continues to be a target of cyber-attacks that could lead to a disruption of its worldwide operations, including manufacturing, research and sales operations.
•
The Company is increasing its use of